HomeCompareVIRI vs JNJ

VIRI vs JNJ: Dividend Comparison 2026

VIRI yields 1290.32% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIRI wins by $2.3960825995340865e+24M in total portfolio value
10 years
VIRI
VIRI
● Live price
1290.32%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.3960825995340865e+24M
Annual income
$2,395,725,921,261,555,500,000,000,000,000.00
Full VIRI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VIRI vs JNJ

📍 VIRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIRIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIRI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIRI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIRI
Annual income on $10K today (after 15% tax)
$109,677.42/yr
After 10yr DRIP, annual income (after tax)
$2,036,367,033,072,322,200,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, VIRI beats the other by $2,036,367,033,072,322,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIRI + JNJ for your $10,000?

VIRI: 50%JNJ: 50%
100% JNJ50/50100% VIRI
Portfolio after 10yr
$1.1980412997670432e+24M
Annual income
$1,197,862,960,630,777,700,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VIRI
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-882.0
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIRI buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIRIJNJ
Forward yield1290.32%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$2.3960825995340865e+24M$30.3K
Annual income after 10y$2,395,725,921,261,555,500,000,000,000,000.00$4,689.40
Total dividends collected$2.3960592593715676e+24M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: VIRI vs JNJ ($10,000, DRIP)

YearVIRI PortfolioVIRI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$268,765$258,064.52$10,592$272.30+$258.2KVIRI
2$13,251,799$12,964,221.46$11,289$357.73+$13.24MVIRI
3$1,208,980,447$1,194,801,021.45$12,123$472.89+$1208.97MVIRI
4$205,038,263,945$203,744,654,866.63$13,141$629.86+$205038.25MVIRI
5$64,806,832,428,888$64,587,441,486,467.30$14,408$846.81+$64806832.41MVIRI
6$38,226,866,599,812,776$38,157,523,289,113,870.00$16,021$1,151.60+$38226866599.80MVIRI
7$42,111,076,145,403,994,000$42,070,173,398,142,190,000.00$18,122$1,588.22+$42111076145403.98MVIRI
8$86,671,038,474,809,380,000,000$86,625,979,623,333,790,000,000.00$20,930$2,228.20+$86671038474809392.00MVIRI
9$333,344,179,935,764,700,000,000,000$333,251,441,924,596,600,000,000,000.00$24,792$3,191.91+$333344179935764676608.00MVIRI
10$2,396,082,599,534,086,500,000,000,000,000$2,395,725,921,261,555,500,000,000,000,000.00$30,274$4,689.40+$2.3960825995340865e+24MVIRI

VIRI vs JNJ: Complete Analysis 2026

VIRIStock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Full VIRI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VIRI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIRI vs SCHDVIRI vs JEPIVIRI vs OVIRI vs KOVIRI vs MAINVIRI vs ABBVVIRI vs MRKVIRI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.